TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04112147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol capsule 100mg
Description: Patients will receive 12-week of 50mg BID Antroquinonol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol capsule 200mg
Description: Patients will receive 12-week of 100mg BID Antroquinonol
Study: NCT02044302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics
Study: NCT03011827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibrinogen and/or platelets administration
Description: Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
Study: NCT00059930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT04112147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will receive 12-week of 100mg BID Antroquinonol placebo
Study: NCT00324623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melan-A VLP vaccine, IMP321 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adoptive immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study: NCT02287103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping Breakfast
Description: NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eating Breakfast
Description: YesB: will eat all three meals
Study: NCT00246636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antara (fenofibrate) + Lovaza
Description: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antara (fenofibrate) + Lovaza
Description: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antara (fenofibrate)
Description: Antara (fenofibrate) + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antara (fenofibrate)
Description: Antara (fenofibrate) + placebo
Study: NCT04276545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV administration of DEX to investigate the effects for functional nasal endoscopic surgery
Description: IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV administration of DEX to investigate the effects for functional nasal endoscopic surgery
Description: IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery
Description: IV administration of midazolam (0.05mg/kg) after induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery
Description: IV administration of midazolam (0.05mg/kg) after induction.
Study: NCT02595528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 + AGN-190584 Combination
Description: 1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 vehicle
Description: Vehicle to AGN-199201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 vehicle
Description: Vehicle to AGN-199201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 vehicle
Description: Vehicle to AGN-199201
Study: NCT00633321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-NIC
Description: TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-NIC
Description: TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
Study: NCT02595528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 vehicle
Description: Vehicle to AGN-199201
Study: NCT00059930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Study: NCT01947946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 44 inclusive.
Study: NCT01659723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
Study: NCT02252211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8895a 1 mg/kg
Description: Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8895a 3 mg/kg
Description: Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8895a 10 mg/kg
Description: Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Study: NCT03116594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of Oka/SK strain of live, attenuated zoster virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of Oka/SK strain of live, attenuated zoster virus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Preparation of Oka/Merck strain of live, attenuated zoster virus
Study: NCT06042829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation using aerosol box
Description: Intubation time and ease of intubation using aerosol box

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation without aerosol box
Description: Intubation time and ease of intubation without aerosol box
Study: NCT01985126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg (Part 1)
Description: Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
Study: NCT00059930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study: NCT01985126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 8 mg/kg (Part 1)
Description: Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
Study: NCT05221879

Intervention type: OTHER
Group type: OTHER
Intervention: Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a
Description: We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.
Study: NCT04033900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced air warming devices
Description: In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room
Study: NCT01985126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab (Part 2)
Description: Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
Study: NCT00366626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 7 days matched to Naltrexone
Study: NCT01953926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg administered orally, once daily with food, continuously in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg administered orally, once daily with food, continuously in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg administered orally, once daily with food, continuously in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg administered orally, once daily with food, continuously in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg administered orally, once daily with food, continuously in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg administered orally, once daily with food, continuously in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
Study: NCT02255175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Participants will receive transdermal estradiol (100μg/day) for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Participants will receive transdermal estradiol (100μg/day) for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
Study: NCT01602848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive care management and coordination
Description: Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
Study: NCT06163755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 MG Injection
Description: Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone 40 MG Injection
Description: Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
Study: NCT01276587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
Study: NCT03998826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: 20mg piroxicam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00433069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Description: Standard of care for chronic hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Standard of care for chronic hepatitis C
Study: NCT03603431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-110
Description: Single ascending doses of MRG-110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-110
Description: Multiple ascending doses of MRG-110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple doses of Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple doses of Placebo
Study: NCT03031405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo nasal spray
Study: NCT01027884

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
Study: NCT01788059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection the mesenchymal stem cell in non union site
Study: NCT00420160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment plus moderate intensity exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation treatment plus health education
Study: NCT01187160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Description: The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
Study: NCT00184431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy technique and exercises
Description: The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy technique and exercises
Description: The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
Study: NCT02038101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Feedback
Description: 1. Formal Rounds on AUC for TTE~2. Appropriate Use for TTE Application for Smartphone~3. Individualized Feedback Reports provided by email
Study: NCT01168700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aged garlic extract
Description: Aged garlic extract, 1.2 g per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.2 g per day for 12 weeks.
Study: NCT01692080

Intervention type: BEHAVIORAL
Intervention: Asthma education
Description: Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
Study: NCT02446665

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MR Elastography (MRE) and FibroScan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Elastography (MRE) and FibroScan
Study: NCT05617573

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty due to advanced osteoarthritis.
Description: Postoperative usage of intravenous methylprednisolone
Study: NCT03912688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single acupoint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual acupoints